News Center – Page 2 – MedAvante-ProPhase

Simplified Negative and Positive Symptoms Interview (SNAPSI): An Abbreviated Assessment Technique for Schizophrenia Studies

February 21, 2018

Analysis of the methodological question can the PANSS be modified to be useable in clinical settings as well as in research? presented at the 14th ISCTM Scientific Conference. Authors propose...

Identifying Elevated Rates of CDR Scoring Errors: The Cognitive-Functional Difference Score

November 1, 2017

At 10th Clinical Trials on Alzheimer’s Disease (CTAD) MedAvante-ProPhase presented research and analysis addressing the need to identify administrations of the Clinical Dementia Rating scale (CDR) within clinical trials that...

Subjective Interview Quality Metrics Predict Scoring Performance in the Administration of the PANSS

September 1, 2017

MedAvante presented research at the 30th European College of Neuropsychopharmacology (ECNP) Congress showing that subjective interview quality metrics are predictive of in-study scoring performance and can serve as a useful...

Impact of Centralized Over-Read on Outcomes in Depression and Schizophrenia Trials

August 31, 2017

Research presented at the 2017 International Society for CNS Clinical Trials and Methodology (ISCTM) Fall Conference examined Central Review of two widely used efficacy measures administered in schizophrenia and depression...

The RBANS as a Useful Outcome Measure in Prodromal AD Trials

July 17, 2017

The RBANS total scale index score correlated with the CDR-SB, and decreased in a linear fashion with increasing CDR-SB, even within a limited range of CDR-SB scores and without evidence...

Increased Signal Detection in Alzheimer’s Disease Clinical Trials

July 14, 2017

Research presented at 2017 Alzheimer’s Association International Conference (AAIC) demonstrates that increased lag time between administrations of COAs significantly increases error rates on three of the most commonly used and...